人工智能指导的产科人群心肌病筛查:一项实用性随机临床试验
在尼日利亚6家医院开展的开放标签实用性随机试验,将1232名妊娠及产后女性随机分为常规护理组与AI指导筛查组,评估AI筛查对围产期左心室收缩功能障碍(LVSD)诊断的影响。AI数字听诊器筛查组LVSD检出24/587(4.1%)vs 对照组12/608(2.0%),比值比2.12(95%CI 1.05-4.27;P=0.032);AI心电图模型检出20/587(3.4%)vs 12/608(2.0%),比值比1.75(95%CI 0.85-3.62;P=0.125)。AI指导的数字听诊器筛查改善了妊娠相关心肌病的诊断。
要点
- AI数字听诊器筛查组LVSD检出率4.1% vs 对照组2.0%,比值比2.12(95%CI 1.05-4.27;P=0.032)。
- AI心电图模型筛查组LVSD检出率3.4% vs 对照组2.0%,比值比1.75(95%CI 0.85-3.62;P=0.125),未达统计学显著。
- 预设亚组分析观察到相似方向效应,无与研究参与相关的严重不良事件。
核心结论
- 在妊娠及产后女性中,使用数字听诊器的AI指导筛查改善了妊娠相关心肌病的诊断。
研究设计与样本
- 开放标签实用性随机临床试验,在尼日利亚6家医院于2022年8月至2023年9月完成基线访视并随访至2024年5月。
- 共1232名妊娠及产后女性随机分组(每组616名),1195名完成基线访视(干预组587名,对照组608名)。
- 干预组接受数字听诊器录音联合床旁AI预测及12导联心电图异步AI预测筛查LVSD,对照组接受常规护理。
- 主要终点为研究期间LVSD的识别;干预组以AI筛查阳性并经超声心动图确认的LVSD参与者数定义,对照组以常规护理下超声心动图临床识别并记录的LVSD参与者数定义。
- 干预组参与者在基线接受确认性超声心动图用于AI模型验证。
主要发现
- AI数字听诊器筛查组主要终点检出24/587(4.1%)vs 对照组12/608(2.0%),干预组 vs 对照组比值比2.12(95%CI 1.05-4.27;P=0.032)。
- 12导联AI心电图模型检出主要终点20/587(3.4%)vs 对照组12/608(2.0%),比值比1.75(95%CI 0.85-3.62;P=0.125)。
- 预设亚组分析观察到相似方向效应。
- 无与研究参与相关的严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nigeria has the highest reported incidence of peripartum cardiomyopathy worldwide. This open-label, pragmatic clinical trial randomized pregnant and postpartum women to usual care or artificial intelligence (AI)-guided screening to assess its impact on the diagnosis left ventricular systolic dysfunction (LVSD) in the perinatal period. The study intervention included digital stethoscope recordings with point of-care AI predictions and a 12-lead electrocardiogram with asynchronous AI predictions for LVSD. The primary end point was identification of LVSD during the study period. In the intervention arm, the primary end point was defined as the number of identified participants with LVSD as determined by a positive AI screen, confirmed by echocardiography. In the control arm, this was the number of participants with clinical recognition and documentation of LVSD on echocardiography in keeping with current standard of care. Participants in the intervention arm had a confirmatory echocardiogram at baseline for AI model validation. A total of 1,232 (616 in each arm) participants were randomized and 1,195 participants (587 intervention arm and 608 control arm) completed the baseline visit at 6 hospitals in Nigeria between August 2022 and September 2023 with follow-up through May 2024. Using the AI-enabled digital stethoscope, the primary study end point was met with detection of 24 out of 587 (4.1%) versus 12 out of 608 (2.0%) patients with LVSD (intervention versus control odds ratio 2.12, 95% CI 1.05-4.27; P = 0.032). With the 12-lead AI-electrocardiogram model, the primary end point was detected in 20 out of 587 (3.4%) versus 12 out of 608 (2.0%) patients (odds ratio 1.75, 95% CI 0.85-3.62; P = 0.125). A similar direction of effect was observed in prespecified subgroup analysis. There were no serious adverse events related to study participation. In pregnant and postpartum women, AI-guided screening using a digital stethoscope improved the diagnosis of pregnancy-related cardiomyopathy. ClinicalTrials.gov registration: NCT05438576.
引用
- Adedinsewo DA, Morales-Lara AC, Afolabi BB, et al. Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial. Nat Med. 2024. PMID: 39223284. doi:10.1038/s41591-024-03243-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。